Evonik realigns its Health Care business to maximize customer centricity
- Three new product lines with stronger focus on markets
- Customer-first, consolidated portfolio
- Advanced system solutions approach for core pharma markets
Essen, Germany. Evonik is transforming its Health Care business to maximize customer centricity and market focus. Effective April 1, 2022, the company will streamline its operations into three new product lines: Drug Delivery & Product, Drug Substance, and Health Solutions. Each product line builds on core competencies and broad differentiating technology platforms to meet the specific requirements of diverse healthcare markets.
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries. As part of the Nutrition & Care division, the Health Care business plays a key role in increasing the division’s share of system solutions from 20 percent today to more than 50 percent by 2030.
“This strategic transformation of our business line will unleash innovation and new service potential – for the benefit of our customers and patients. We’re proud to be the preferred development and manufacturing partner for the industry’s most innovative therapies,” says Dr Thomas Riermeier, head of Evonik’s Health Care business line.
The "Drug Delivery & Products" unit, headed by Paul Spencer, focuses on advancing the company’s system solutions for advanced oral and parenteral drug delivery. This includes the strong portfolio of excipients (like EUDRAGIT® and RESOMER®), lipids, and lipid nanoparticles (LNPs), with complementary CDMO services from feasibility studies to commercial drug products. Spencer has been working in the pharmaceutical industry for more than 30 years and has extensive experience in drug delivery and biomaterials.
The new unit “Drug Substance” encompasses the company’s custom development and manufacturing organization (CDMO) services for active pharmaceutical ingredients (APIs) and intermediates as well as its portfolio of API products. Building on strong piloting and world-scale facilities in the U.S. and Germany, Evonik supports customers with scale-up from clinical phases to commercial production, including large-scale high potency APIs (HPAPI) and multi-step complex APIs. The new unit is led by Dr Stefan Randl. With over 15 years’ experience in the biotech, pharma, and chemical industries, Randl is accomplished in the industrialization of pharma processes. Since 2020, he has been leading projects to strengthen Evonik’s position in mRNA and gene therapies.
Under the leadership of Maximillian Yeh, the "Health Solutions" product line will focus on fast-growing markets. The unit brings together the biopharma solutions, medical device solutions, and advanced food ingredients solutions businesses. Yeh was previously responsible for the global sales organization of the Health Care business line and has more than 30 years’ experience in the chemical and pharmaceutical industry.
Company information
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
